Harvard Bioscience Company Leadership

Harvard Bioscience Management Team Effectiveness

As of the 24th of January 2026, Return On Tangible Assets is likely to drop to -0.2. In addition to that, Return On Capital Employed is likely to grow to -0.09. At this time, Harvard Bioscience's Total Current Assets are very stable compared to the past year. As of the 24th of January 2026, Other Current Assets is likely to grow to about 4.2 M, while Total Assets are likely to drop about 125.2 M. Harvard Bioscience's management efficiency ratios could be used to measure how well Harvard Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of January 2026, Common Stock Shares Outstanding is likely to drop to about 33.7 M. In addition to that, Net Loss is likely to grow to about (8.1 M)Harvard Bioscience has a total of 44.58 Million outstanding shares. 30% of Harvard Bioscience outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Harvard Bioscience in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Harvard Bioscience, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Harvard Bioscience Workforce Comparison

Harvard Bioscience Profit Margins

The company has Profit Margin (PM) of (0.62) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.01 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.01.

Harvard Bioscience Insider Trading

Harvard Bioscience Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Harvard Bioscience often depends on how effective the management is. Harvard Bioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Harvard management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Harvard management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.